Page 3 - Gsk Pharma

Crocin 2.0: GSK is reinventing the pain-reliever brand to keep it relevant

The British multinational adds a fresh extension to its 40-year-old flagship, hopes to leverage the brand's recall to expand its remedial reach

GSK gains 38% over 3 months, gets boost from tighter low-end portfolio

Revenue growth, margins have been trending up over the past couple of quarters

As price pressure mounts, pharma companies tap analytics to cut costs

Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution

GSK Pharma's health gets boost from focus on top brands' yields

The company is focusing completely on promoting its top twenty brands, including the antibiotic Augmentin, and antipyretic Calpol

Price revisions, new products should add to GSK Pharma's top-line growth

Brands, vaccines to drive margins for GSK Pharma

GSK Pharma's September-quarter profit down 23% to Rs 1.01 billion

The company had posted a net profit of Rs 130.32 crore in the year-ago period, GSK Pharma said in a BSE filing

GST impact: GSK Pharma's June quarter profit down 64% on de-stocking

Stockists were holding 17 days' inventory by end of June, which was 23 days lower than May-end stock

GSK Pharma's underperformance to continue

While there are some signs of sales revival, re-rating would require consistent growth

Govt price controls affect GSK Pharma's results

Company will have to improve volumes, cut costs to overcome impact of lower pricing